THE Therapeutic Goods Administration (TGA) has advised health professionals that it has re-categorised hyperthyroidism treatments, propylthiouracil and carbimazole, for use in pregnancy following reported cases of congenital abnormalities.
The medications have moved to pregnancy Category D, which is defined as, "drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human foetal malformations or irreversible damage and reflects the post-market experience with these medicines".
CLICK HERE for more.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Sep 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Sep 21